| Filed On | Filing |
|---|---|
| 16 Nov 2026 | FORM 10-Q |
| 05 Nov 2026 | FORM DEFA14A |
| 05 Nov 2026 |
Proxy statement: annual meeting on December 17, 2026
CEO pay $885K |
| 04 Nov 2026 |
Form 4: Abrams Michael S, Chief Financial Officer
Granted 75,000 Restricted Stock Unit |
| 04 Nov 2026 |
Form 4: Javitt Jonathan C, Director
Granted 150,000 Restricted Stock Unit |
| 02 Nov 2026 |
8-K: Regulation FD Disclosure
Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA. Current law requ... |
| 16 Oct 2026 |
8-K: Other Events
On October 16, 2026, the board of directors (the “Board”) of NRx Pharmaceuticals, Inc. (the “Company”) established December 17, 2026 as the date of the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) and set October 28, 2... |
| 05 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression |
| 16 Sep 2026 |
8-K: Other Events
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
On September 8, 2026, representatives of NRx Pharmaceuticals, Inc. (the “Company”) used the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K in connection with presentations and meetings with investors a... |
| 17 Aug 2026 |
8-K: Results of Operations and Financial Condition
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET |
| 14 Aug 2026 | FORM 10-Q |
| 07 Aug 2026 |
8-K: Regulation FD Disclosure
As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination ... |
| 22 Jul 2026 |
8-K: Other Events
In April 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced the incorporation of NRx Defense Systems, Inc. (“NRXD”), a Florida-based research and development subsidiary charged with the development of neuroplastic treatments that ... |
| 04 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
NRx Pharmaceutics, Inc., a Delaware corporation (the “Company”) proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter prov... |
| 03 Jun 2026 | FORM 424B5 |
| 02 Jun 2026 |
8-K: Other Events
WILMINGTON, Del., June 2, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer shares of its comm... |
| 02 Jun 2026 | FORM 424B5 |
| 22 May 2026 | 25-NSE |
| 15 May 2026 | FORM 10-Q |
Loading...